Fundz

Epicrispr Biotechnologies and Forge Biologics Announce Strategic Partnership for AAV Development and Manufacturing of EPI-321.

May 05, 2026

Contract Type

partnership

San FranciscoBiotechnologyHealth CareGeneticsTherapeutics

Description

Epicrispr Biotechnologies and Forge Biologics have entered a partnership to support the development of EPI-321, Epicrispr's investigational gene therapy for FSHD. Forge will provide cGMP manufacturing services and process development for this clinical trial across the U.S., New Zealand, and Australia.

Company Information

Company

Epicrispr Biotechnologies

Location

San Francisco, California, United States

About

Epicrispr Biotechnologies is a biotechnology company focused on developing curative therapies for genetic neuromuscular diseases. Their lead program, EPI-321, is a first-in-class disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD). The company aims to advance innovative treatments that address the underlying causes of genetic disorders. With recent funding, Epicrispr is entering the clinical stage to bring much-needed therapies to patients.

Related People

Alexandra
Senior decision-maker at this company
••••••••@••••••••

See Alexandra's verified email →

Daniel
Senior decision-maker at this company
••••••••@••••••••

See Daniel's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Epicrispr Biotechnologies's next move

Learn about Strategic plan

Agreement Insights

What this usually means
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies

Epicrispr Biotechnologies signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.